NASDAQ:NBSE - NeuBase Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 1,100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.00
+0.30 (1.20%)

This chart shows the closing price for NBSE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuBase Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBSE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBSE

Analyst Price Target is $12.00
▲ +1,100.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for NeuBase Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,100.00% upside from the last price of $1.00.

This chart shows the closing price for NBSE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in NeuBase Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Chardan CapitalLower Price Target$18.00 ➝ $9.00Medium
1/3/2022HC WainwrightReiterated RatingBuyHigh
9/13/2021HC WainwrightReiterated RatingBuy$15.00High
6/1/2021HC WainwrightLower Price TargetBuy$18.00 ➝ $15.00Low
3/18/2021OppenheimerReiterated RatingBuy$17.00High
2/12/2021HC WainwrightBoost Price TargetBuy$15.00 ➝ $18.00Low
12/27/2020Royal Bank of CanadaReiterated RatingBuy$17.00N/A
12/17/2020HC WainwrightReiterated RatingBuyMedium
8/16/2020Royal Bank of CanadaReiterated RatingBuy$16.00Medium
8/14/2020Chardan CapitalReiterated RatingBuyHigh
7/16/2020OppenheimerReiterated RatingBuy$17.00Low
6/16/2020Royal Bank of CanadaInitiated CoverageOutperform$16.00High
5/19/2020HC WainwrightReiterated RatingBuy$15.00Low
5/18/2020OppenheimerInitiated CoverageBuy$17.00Low
5/6/2020HC WainwrightReiterated RatingBuy$15.00Low
4/1/2020OppenheimerBoost Price TargetOutperform$14.00 ➝ $17.00High
4/1/2020Chardan CapitalBoost Price TargetBuy$14.00 ➝ $18.00High
3/19/2020Chardan CapitalReiterated RatingBuy$14.00High
3/6/2020Chardan CapitalInitiated CoverageBuy$14.00Medium
2/6/2020GuggenheimInitiated CoverageBuy$13.00High
12/2/2019HC WainwrightReiterated RatingBuy$14.00High
11/20/2019OppenheimerInitiated CoverageOutperform$14.00High
10/29/2019HC WainwrightInitiated CoverageBuy$14.00High
9/24/2019BTIG ResearchInitiated CoverageBuy$15.00High
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/26/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/25/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/24/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/23/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/24/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/24/2022

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
NeuBase Therapeutics logo
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Read More

Today's Range

Now: $1.00
Low: $1.00
High: $1.04

50 Day Range

MA: $1.48
Low: $0.90
High: $2.01

52 Week Range

Now: $1.00
Low: $0.89
High: $5.51

Volume

33,230 shs

Average Volume

116,053 shs

Market Capitalization

$32.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuBase Therapeutics?

The following Wall Street analysts have issued stock ratings on NeuBase Therapeutics in the last twelve months: Chardan Capital, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for NBSE.

What is the current price target for NeuBase Therapeutics?

0 Wall Street analysts have set twelve-month price targets for NeuBase Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 1,100.0%.
View the latest price targets for NBSE.

What is the current consensus analyst rating for NeuBase Therapeutics?

NeuBase Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NBSE will outperform the market and that investors should add to their positions of NeuBase Therapeutics.
View the latest ratings for NBSE.

How do I contact NeuBase Therapeutics' investor relations team?

NeuBase Therapeutics' physical mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The company's listed phone number is (164) 645-1790 and its investor relations email address is [email protected] The official website for NeuBase Therapeutics is www.neubasetherapeutics.com. Learn More about contacing NeuBase Therapeutics investor relations.